Even though BAFF-R is expressed at lower levels than CD19, anti-BAFF-R CAR T cells have shown preclinical efficacy against a wide range of lymphoma and chronic lymphocytic leukemia (CLL) cell lines.20 This evidence concerns the gene TNFRSF13C and lymphoma.